Detalhe da pesquisa
1.
Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis.
Clin Gastroenterol Hepatol
; 21(2): 456-466.e7, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35934286
2.
Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn's Disease: ENTERPRISE Study.
Clin Gastroenterol Hepatol
; 20(5): 1059-1067.e9, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34597729
3.
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis.
Clin Gastroenterol Hepatol
; 20(1): 126-135, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33039584
4.
Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis.
BMC Gastroenterol
; 22(1): 501, 2022 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36474165
5.
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.
Clin Gastroenterol Hepatol
; 18(13): 2952-2961.e8, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32062041
6.
Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases.
Clin Gastroenterol Hepatol
; 17(1): 130-138.e7, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29857145
7.
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.
Clin Gastroenterol Hepatol
; 17(12): 2497-2505.e1, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30625408
8.
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.
Gastroenterology
; 155(3): 687-695.e10, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29857091
9.
Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies.
Dig Dis Sci
; 64(9): 2478-2488, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30923985
10.
Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis.
Am J Gastroenterol
; 113(1): 58-71, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29206816
11.
Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.
Am J Gastroenterol
; 113(12): 696, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30390030
12.
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.
Am J Gastroenterol
; 113(9): 1345, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29946178
13.
Corrigendum: 2016 ACG Abstracts-Inflammatory Bowel Disease.
Am J Gastroenterol
; 112(7): 1209-1210, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28071657
14.
Seasonal patterns of abdominal pain consultations among adults and children.
J Pediatr Gastroenterol Nutr
; 56(3): 290-6, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23059641
15.
Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn's Disease: Post Hoc Analyses of VISIBLE Studies.
Crohns Colitis 360
; 5(3): otad034, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37636008
16.
Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome.
Am J Physiol Gastrointest Liver Physiol
; 303(7): G775-85, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22837345
17.
Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis.
Expert Rev Gastroenterol Hepatol
; 15(6): 711-722, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33599181
18.
Performance Characteristics of a Clinical Decision Support Tool for Disease Complications in Crohn's Disease.
Crohns Colitis 360
; 3(4): otab074, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36777269
19.
Early Intervention With Vedolizumab on Longer Term Surgery Rates in Crohn's Disease: Post Hoc Analysis of the GEMINI Phase 3 and Long-term Safety Programs.
J Crohns Colitis
; 2020 Jul 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32691844
20.
Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis.
J Crohns Colitis
; 14(5): 575-587, 2020 Jun 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-31901085